[go: up one dir, main page]

FR2840532B1 - Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s) - Google Patents

Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)

Info

Publication number
FR2840532B1
FR2840532B1 FR0207175A FR0207175A FR2840532B1 FR 2840532 B1 FR2840532 B1 FR 2840532B1 FR 0207175 A FR0207175 A FR 0207175A FR 0207175 A FR0207175 A FR 0207175A FR 2840532 B1 FR2840532 B1 FR 2840532B1
Authority
FR
France
Prior art keywords
lipid
nanocapsules
preparation
lipid nanocapsules
furent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0207175A
Other languages
English (en)
Other versions
FR2840532A1 (fr
Inventor
Didier Hoarau
Pascal Delmas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0207175A priority Critical patent/FR2840532B1/fr
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Priority to PCT/IB2003/003213 priority patent/WO2003103822A2/fr
Priority to US10/458,324 priority patent/US20040076683A1/en
Priority to MXPA04012567A priority patent/MXPA04012567A/es
Priority to CN038137437A priority patent/CN1658845A/zh
Priority to NZ537393A priority patent/NZ537393A/en
Priority to BR0314767-3A priority patent/BR0314767A/pt
Priority to US10/518,173 priority patent/US20050214378A1/en
Priority to EP03757174A priority patent/EP1531800B1/fr
Priority to CA002488385A priority patent/CA2488385A1/fr
Priority to ES03757174T priority patent/ES2366978T3/es
Priority to JP2004510937A priority patent/JP2005532355A/ja
Priority to DK03757174.2T priority patent/DK1531800T3/da
Priority to AT03757174T priority patent/ATE511834T1/de
Priority to AU2003247061A priority patent/AU2003247061B2/en
Publication of FR2840532A1 publication Critical patent/FR2840532A1/fr
Priority to IL165603A priority patent/IL165603A/en
Priority to NO20050153A priority patent/NO333811B1/no
Priority to ZA2005/00228A priority patent/ZA200500228B/en
Application granted granted Critical
Publication of FR2840532B1 publication Critical patent/FR2840532B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0207175A 2002-06-01 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s) Expired - Fee Related FR2840532B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0207175A FR2840532B1 (fr) 2002-06-11 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
JP2004510937A JP2005532355A (ja) 2002-06-11 2003-06-11 ステルス脂質ナノカプセル、その製造方法、およびその、活性要素用キャリヤーとしての使用
MXPA04012567A MXPA04012567A (es) 2002-06-11 2003-06-11 Nanocapsulas lipidicas encubiertas, metodos para la preparacion de las mismas y uso de las mismas como un portador para principios activos.
CN038137437A CN1658845A (zh) 2002-06-11 2003-06-11 隐形脂质纳米胶囊,其制备方法,及其作为活性成分载体的应用
NZ537393A NZ537393A (en) 2002-06-11 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
BR0314767-3A BR0314767A (pt) 2002-06-11 2003-06-11 Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s)
US10/518,173 US20050214378A1 (en) 2002-06-11 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
EP03757174A EP1531800B1 (fr) 2002-06-11 2003-06-11 Nanocapsules lipidiques indetectables, procedes de preparation de celles-ci et utilisation de ces nanocapsules en tant que support de principe(s) actif(s)
CA002488385A CA2488385A1 (fr) 2002-06-11 2003-06-11 Nanocapsules lipidiques indetectables, procedes de preparation de celles-ci et utilisation de ces nanocapsules en tant que support de principe(s) actif(s)
AT03757174T ATE511834T1 (de) 2002-06-11 2003-06-11 Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)
PCT/IB2003/003213 WO2003103822A2 (fr) 2002-06-01 2003-06-11 Nanocapsules lipidiques indetectables, procedes de preparation de celles-ci et utilisation de ces nanocapsules en tant que support de principe(s) actif(s)
US10/458,324 US20040076683A1 (en) 2002-06-11 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof, and use thereof as a carrier for active principle(s)
ES03757174T ES2366978T3 (es) 2002-06-11 2003-06-11 Nanocápsulas lipídicas furtivas, procedimientos para su preparación y utilización de las mismas como vehículo para principio(s) activo(s).
AU2003247061A AU2003247061B2 (en) 2002-06-11 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
DK03757174.2T DK1531800T3 (da) 2002-06-11 2003-06-11 Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per)
IL165603A IL165603A (en) 2002-06-11 2004-12-07 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
NO20050153A NO333811B1 (no) 2002-06-11 2005-01-11 Stealth-nanokapsler, fremgangsmåter for fremstilling derav og anvendelse som en bærer for aktivt prinsipp/aktive prinsipper
ZA2005/00228A ZA200500228B (en) 2002-06-11 2005-01-11 Stealth lipid nanocapsules methods for the preparation therof and use thereof as a carrier for active principle(s)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207175A FR2840532B1 (fr) 2002-06-11 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)

Publications (2)

Publication Number Publication Date
FR2840532A1 FR2840532A1 (fr) 2003-12-12
FR2840532B1 true FR2840532B1 (fr) 2005-05-06

Family

ID=29559140

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0207175A Expired - Fee Related FR2840532B1 (fr) 2002-06-01 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)

Country Status (5)

Country Link
US (1) US20040076683A1 (fr)
AT (1) ATE511834T1 (fr)
DK (1) DK1531800T3 (fr)
ES (1) ES2366978T3 (fr)
FR (1) FR2840532B1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
FR2916974B1 (fr) * 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
FR2916973B1 (fr) 2007-06-11 2010-02-26 Univ Angers Nanocapsules a coeur lipidique chargees en actif(s) hydrosoluble(s) ou hydrodispersible(s)
FR2939699B1 (fr) 2008-12-12 2011-05-06 Univ Angers Procede de preparation de nanoparticules lipidiques
AU2011203890B2 (en) * 2010-01-11 2013-05-30 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma
CA2833413C (fr) 2011-04-20 2020-09-22 The University Of Sydney Procede pour le traitement d'une tumeur solide
EP2788020A4 (fr) 2011-12-05 2015-04-29 Immunomedics Inc Utilisation thérapeutique d'anticorps anti-cd22 pour induire une trogocytose
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
FR3017294B1 (fr) * 2014-02-07 2021-10-01 Atlangram Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie
CA2981543A1 (fr) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, detection, diagnostic et/ou caracterisation de cellules cancereuses trop-2 positives
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3413914A4 (fr) 2016-02-10 2019-10-16 Immunomedics, Inc. La combinaison inhibiteurs abcg2-sacituzumab govitécan (immu-132) surmonte la résistance à sn-38 dans les cancers exprimant trop-2
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
RU2758234C2 (ru) 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
WO2019213538A1 (fr) * 2018-05-03 2019-11-07 L.E.A.F. Holdings Group Llc Compositions de caroténoïdes et leurs utilisations
EP3679928A1 (fr) 2019-01-08 2020-07-15 Atlangram Composition pharmaceutique de type gel pour traiter/prevenir une infection
FR3099069A1 (fr) * 2019-07-24 2021-01-29 Université D`Angers Procede continu de nano-emulsification par inversion de phase en concentration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
ES2661728T3 (es) * 2005-10-03 2018-04-03 Pinksky, Mark A. Composiciones y métodos para el cuidado mejorado de la piel

Also Published As

Publication number Publication date
US20040076683A1 (en) 2004-04-22
DK1531800T3 (da) 2011-07-11
FR2840532A1 (fr) 2003-12-12
ATE511834T1 (de) 2011-06-15
ES2366978T3 (es) 2011-10-27

Similar Documents

Publication Publication Date Title
FR2840532B1 (fr) Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
Jeong et al. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide
US20210121411A1 (en) Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
Arima et al. Potential use of cyclodextrins as drug carriers and active pharmaceutical ingredients
CA2468916A1 (fr) Formulations pharmaceutiques renfermant un derive du platine
Tila et al. Functional liposomes in the cancer-targeted drug delivery
CN101015525B (zh) 紫杉醇脂质体及其制备方法
Zhang et al. Autocatalytic Delivery of Brain Tumor–Targeting, Size‐Shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases
WO2003043631A3 (fr) Procede d'identification d'enzymes de ciblage de tumeurs
CN100396287C (zh) 含有电子转移剂磷酸盐衍生物的制剂
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
JP2001002565A5 (fr)
NO20050153L (no) Stealth-nanokapsler, fremgangsmater for fremstilling derav og anvendelse som en baerer for aktivt prinsipp/aktive prinsipper
JP2022169627A (ja) 腋臭を治療する方法
JP6482570B2 (ja) 経皮吸収促進剤及び経皮吸収促進助剤
Agardan et al. Redox-triggered intracellular siRNA delivery
Japir et al. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy
EP0992509A3 (fr) Nouveaux dérivés macrolides
EP1968638B1 (fr) Gels à libération contrôlée
JPH10503194A (ja) 多くの異なる活性成分を含有する医薬組成物、主として腟座薬
HU228026B1 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
EP0128338B1 (fr) Pseudomonate d'argent, compositions le contenant et son application au traitement d'infections pseudomoniques
WO2006065888A3 (fr) Systeme de distribution de chelateur du fer cible
CA2283739A1 (fr) Acide ascorbique agissant comme adjuvant dans le traitement de tumeurs malignes par chimiotherapie et radiotherapie

Legal Events

Date Code Title Description
GC Lien (pledge) constituted

Effective date: 20140519

PLFP Fee payment

Year of fee payment: 14

GC Lien (pledge) constituted

Effective date: 20160120

RG Lien (pledge) cancelled

Effective date: 20160226

PLFP Fee payment

Year of fee payment: 15

RG Lien (pledge) cancelled

Effective date: 20170418

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20200205